First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

INTRODUCTION: Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. This retrospective chart review study aimed to describe re...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Tamura, Atsuhisa, Matsumoto, Hirotaka, Isobe, Kazutoshi, Ozaki, Tomohiro, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Nokihara, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440307/
https://www.ncbi.nlm.nih.gov/pubmed/36065450
http://dx.doi.org/10.1016/j.jtocrr.2022.100397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440307/
https://www.ncbi.nlm.nih.gov/pubmed/36065450
http://dx.doi.org/10.1016/j.jtocrr.2022.100397

Ejemplares similares